Tag
New research proposes clear, patient-anchored criteria for defining chronic cough control, highlighting that fewer patients achieve true cough relief than previously thought, underscoring the need for improved therapies.
A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.
This large-scale longitudinal study reveals that chronic cough is linked with widespread grey matter volume reductions and accelerated brain atrophy, highlighting potential neurostructural underpinnings of cough hypersensitivity.
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential a
